Thanks to its overexpression in prostate tumors and its highly restricted expression in humans, we proposed to use SIM2 as an immunotherapy target and were able to identify 5 HLA-A2.1, SIM2-derived immunogenic epitopes [12]. This evidence concerns the gene SIM2 and prostate neoplasm.